Literature DB >> 33562532

Large-Scale Proteomic Analysis of Follicular Lymphoma Reveals Extensive Remodeling of Cell Adhesion Pathway and Identifies Hub Proteins Related to the Lymphomagenesis.

Kamila Duś-Szachniewicz1, Grzegorz Rymkiewicz2, Anil Kumar Agrawal3, Paweł Kołodziej4, Jacek R Wiśniewski5.   

Abstract

Follicular lymphoma (FL) represents the major subtype of indolent B-cell non-Hodgkin lymphomas (B-NHLs) and results from the malignant transformation of mature B-cells in lymphoid organs. Although gene expression and genomic studies have identified multiple disease driving gene aberrations, only a few proteomic studies focused on the protein level. The present work aimed to examine the proteomic profiles of follicular lymphoma vs. normal B-cells obtained by fine-needle aspiration biopsy (FNAB) to gain deep insight into the most perturbed pathway of FL. The cells of interest were purified by magnetic-activated cell sorting (MACS). High-throughput proteomic profiling was performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and allowed to identify of 6724 proteins in at least 75% of each group of samples. The 'Total Protein Approach' (TPA) was applied to the absolute quantification of proteins in this study. We identified 1186 differentially abundant proteins (DAPs) between FL and control samples, causing an extensive remodeling of several molecular pathways, including the B-cell receptor signaling pathway, cellular adhesion molecules, and PPAR pathway. Additionally, the construction of protein-protein interactions networks (PPINs) and identification of hub proteins allowed us to indicate the key player proteins for FL pathology. Finally, ICAM1, CD9, and CD79B protein expression was validated in an independent cohort by flow cytometry (FCM), and the results were consistent with the mass spectrometry (MS) data.

Entities:  

Keywords:  cellular adhesion molecules (CAMs); differentially abundant proteins (DAPs); follicular lymphoma (FL); hub proteins; label-free quantitative proteomics; protein-protein interaction network (PPIN)

Year:  2021        PMID: 33562532      PMCID: PMC7915278          DOI: 10.3390/cancers13040630

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  94 in total

1.  Fast and sensitive total protein and Peptide assays for proteomic analysis.

Authors:  Jacek R Wiśniewski; Fabienne Z Gaugaz
Journal:  Anal Chem       Date:  2015-04-09       Impact factor: 6.986

2.  Follicular lymphoma genomics.

Authors:  Lucy Pickard; Giuseppe Palladino; Jessica Okosun
Journal:  Leuk Lymphoma       Date:  2020-05-19

3.  Vav1 in hematologic neoplasms, a mini review.

Authors:  Matthew J Oberley; Deng-Shun Wang; David T Yang
Journal:  Am J Blood Res       Date:  2012-01-01

4.  Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.

Authors:  John F Seymour; Robert Marcus; Andrew Davies; Eve Gallop-Evans; Andrew Grigg; Andrew Haynes; Michael Herold; Thomas Illmer; Herman Nilsson-Ehle; Martin Sökler; Ulrich Dünzinger; Tina Nielsen; Aino Launonen; Wolfgang Hiddemann
Journal:  Haematologica       Date:  2020-05       Impact factor: 9.941

5.  Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.

Authors:  June H Myklebust; Joshua Brody; Holbrook E Kohrt; Arne Kolstad; Debra K Czerwinski; Sébastien Wälchli; Michael R Green; Gunhild Trøen; Knut Liestøl; Klaus Beiske; Roch Houot; Jan Delabie; Ash A Alizadeh; Jonathan M Irish; Ronald Levy
Journal:  Blood       Date:  2016-12-23       Impact factor: 22.113

6.  Overexpression of the VAV proto-oncogene product is associated with B-cell chronic lymphocytic leukaemia displaying loss on 13q.

Authors:  Rosario M Prieto-Sánchez; José A Hernández; Juan L García; Norma C Gutiérrez; Jesús San Miguel; Xosé R Bustelo; Jesús M Hernández
Journal:  Br J Haematol       Date:  2006-06       Impact factor: 6.998

7.  Quantification of cellular adhesion molecules on malignant B cells from non-Hodgkin's lymphoma.

Authors:  M C Jacob; S Agrawal; L Chaperot; C Giroux; R Gressin; F Le Marc'Hadour; M Favre; J J Sotto; J C Bensa; J Plumas
Journal:  Leukemia       Date:  1999-09       Impact factor: 11.528

8.  Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.

Authors:  J L Schultze; A A Cardoso; G J Freeman; M J Seamon; J Daley; G S Pinkus; J G Gribben; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

9.  Physiological Hypoxia (Physioxia) Impairs the Early Adhesion of Single Lymphoma Cell to Marrow Stromal Cell and Extracellular Matrix. Optical Tweezers Study.

Authors:  Kamila Duś-Szachniewicz; Sławomir Drobczyński; Piotr Ziółkowski; Paweł Kołodziej; Kinga M Walaszek; Aleksandra K Korzeniewska; Anil Agrawal; Piotr Kupczyk; Marta Woźniak
Journal:  Int J Mol Sci       Date:  2018-06-26       Impact factor: 5.923

10.  Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.

Authors:  Emmanuel Bachy; John F Seymour; Pierre Feugier; Fritz Offner; Armando López-Guillermo; David Belada; Luc Xerri; John V Catalano; Pauline Brice; François Lemonnier; Alejandro Martin; Olivier Casasnovas; Lars M Pedersen; Véronique Dorvaux; David Simpson; Sirpa Leppa; Jean Gabarre; Maria G da Silva; Sylvie Glaisner; Loic Ysebaert; Anne Vekhoff; Tanin Intragumtornchai; Steven Le Gouill; Andrew Lister; Jane A Estell; Gustavo Milone; Anne Sonet; Jonathan Farhi; Harald Zeuner; Hervé Tilly; Gilles Salles
Journal:  J Clin Oncol       Date:  2019-07-24       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.